The comprehensive UK reference on research peptides
Independent, evidence-based profiles spanning healing and regeneration (BPC-157, GHK-Cu), the growth-hormone axis (sermorelin, CJC-1295, ipamorelin), incretin-pathway metabolic peptides (semaglutide, tirzepatide), cognitive nootropics (Semax, Selank), longevity and mitochondrial compounds (SS-31, humanin, MOTS-c), immune modulators, sexual-health melanocortin agonists (PT-141), and cosmetic dermal ingredients.
Featured across categories
One representative profile from each of the site’s principal cluster categories — from healing peptides to MHRA-licensed incretins and central-arousal melanocortin agonists.
BPC-157
Body Protection Compound 157 · PL 14736 · Pentadecapeptide BPC 157
A 15-amino-acid pentadecapeptide derived from a protective protein found in human gastric juice. The most-studied healing research peptide, with extensive pre-clinical work on tendon, ligament, gut, and vascular repair.
GHK-Cu
Copper tripeptide-1 · Glycyl-L-histidyl-L-lysine:copper(II)
A naturally occurring copper-binding tripeptide (Gly-His-Lys) complexed with Cu(II). Extensively studied in dermatology for wound healing, collagen synthesis, antioxidant defence, and hair-follicle stimulation.
Semaglutide
Ozempic · Wegovy · Rybelsus · NN9535 · NN9924 (oral)
A long-acting GLP-1 receptor agonist developed by Novo Nordisk, modified from native GLP-1 with aminoisobutyric acid (Aib) at position 8 (DPP-4 resistance) and a C18 fatty diacid moiety on lysine 26 (albumin binding for ~1-week half-life). Licensed in the UK by the MHRA for type-2 diabetes (Ozempic, subcutaneous; Rybelsus, oral) and chronic weight management (Wegovy, subcutaneous). The most clinically significant GLP-1 receptor agonist of the late 2020s.
Tirzepatide
Mounjaro · Zepbound · LY3298176
A 39-amino-acid synthetic peptide developed by Eli Lilly as a dual GIPR/GLP-1R co-agonist — the first commercially successful dual incretin receptor agonist. Engineered with C20 fatty diacid acylation on lysine 20 for albumin binding and weekly dosing. Licensed in the UK by the MHRA for type-2 diabetes (Mounjaro) and chronic weight management (Zepbound). Produces larger weight loss than semaglutide in head-to-head trials (SURPASS-2, SURMOUNT-5).
Tesamorelin
Egrifta · TH9507 · Tesamorelin acetate · Trans-3-hexenoyl-GHRH 1-44
A stabilised analogue of full-length human GHRH (1-44) with a trans-3-hexenoyl group attached to the N-terminal tyrosine, conferring protease resistance against DPP-4. The only GHRH-analogue compound to hold current FDA approval — licensed as Egrifta (marketed by Theratechnologies) for HIV-associated lipodystrophy. Distinguished from sermorelin and CJC-1295 by its retained full 44-amino-acid sequence rather than the 1-29 truncation.
PT-141 (Bremelanotide)
Bremelanotide · Vyleesi · PT141 · Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
A cyclic heptapeptide melanocortin-receptor agonist developed by Palatin Technologies as a Melanotan II derivative optimised for central-nervous-system sexual-function effects with reduced pigmentation activity. Licensed by the FDA as Vyleesi in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first melanocortin-receptor agonist approved for sexual-function indication. Not licensed in the UK.
Research highlights
Plain-English summaries of recent pre-clinical and translational research across the peptide categories covered on this site, plus the UK regulatory reference.
2026-02-11
BPC-157 in tendon healing — what the 2024 evidence base shows
BPC-157 has the largest and most consistently positive pre-clinical tendon-healing dataset of any research peptide. Across more than two dozen independent rodent studies of Achilles transection, supraspinatus tear, medial collateral ligament injury, and Achilles tendinopathy, treated tendons have shown faster recovery of biomechanical strength, improved collagen fibril alignment, accelerated tenocyte repopulation, and enhanced peritendinous angiogenesis compared with saline controls. The mechanistic story — growth-hormone-receptor upregulation in tenocytes, VEGFR2-driven angiogenesis, and NO-system protection of the peritendinous vasculature — is coherent and reproducible across laboratories. The translation to human tendon care, however, remains entirely unproven: no controlled human trial of BPC-157 for any tendon indication has been published in an indexed journal as of 2024.
Read summary2026-03-02
GHK-Cu and skin regeneration — what the dermal evidence shows
GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) has the strongest dermal regenerative evidence base of any non-prescription peptide ingredient. Five decades of laboratory characterisation, beginning with Pickart's 1973 discovery, have produced a coherent and reproducible picture: copper delivery to cuproenzymes (notably lysyl oxidase), broad transcriptional modulation in human fibroblasts, accelerated wound closure in animal models, and an extensive cosmetic-use safety record. The clinical translation, however, is uneven. Cosmetic-dermatology evidence is substantial; controlled trials in therapeutic wound-care indications are sparse and methodologically heterogeneous. This reference synthesises what the dermal evidence currently supports, what it does not, and where the most useful future research lies.
Read summary2026-04-10
Best healing peptides for research in 2026
This is a 2026 reference list of the most actively studied research peptides for tissue healing, repair, and regeneration. It is organised by evidence-base depth — not by commercial popularity, supplier prominence, or social-media visibility — and applies to laboratory research selection. BPC-157 remains the most-studied research peptide for soft-tissue repair; GHK-Cu leads dermal regeneration; KPV and larazotide dominate gut-barrier research; LL-37 sits at the antimicrobial-host-defence intersection. The peptides included on this list all have indexed peer-reviewed publications, plausible mechanism of action, and at least some independent replication outside the discovering laboratory. Compounds whose evidence is confined to a single laboratory or supplier marketing material are not included.
Read summary2026-05-17
UK research peptide regulation in 2026 — a reference guide
The UK regulatory position on research peptides sits across four distinct frameworks — MHRA medicines licensing, WADA anti-doping classifications, the Misuse of Drugs Act, and the Human Medicines Regulations 2012. This reference explains how each applies, and what the research-versus-supply distinction means in practice.
Read summaryWhere to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.
Stay current on research-peptide developments
One short email per month summarising new pre-clinical and translational research across the peptide categories covered on this site — healing, GH-axis, incretin, cognitive, longevity, and adjacent domains. No promotion, no spam.